OPK icon

Opko Health

1.38 USD
-0.02
1.43%
At close Apr 30, 4:00 PM EDT
After hours
1.34
-0.04
2.90%
1 day
-1.43%
5 days
-6.76%
1 month
-16.87%
3 months
-8.61%
6 months
-9.21%
Year to date
-4.83%
1 year
13.11%
5 years
-37.84%
10 years
-89.97%
0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

17% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 29

2.26% more ownership

Funds ownership: 26.6% [Q3] → 28.86% (+2.26%) [Q4]

8% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 60

4% more capital invested

Capital invested by funds: $278M [Q3] → $289M (+$11.7M) [Q4]

1% less funds holding

Funds holding: 232 [Q3] → 230 (-2) [Q4]

45% less call options, than puts

Call options by funds: $9.74M | Put options by funds: $17.7M

100% less funds holding in top 10

Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$2.25
63%
upside
Avg. target
$2.63
90%
upside
High target
$3
117%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Yi Chen
33% 1-year accuracy
57 / 173 met price target
117%upside
$3
Buy
Reiterated
7 Apr 2025
Barrington Research
Michael Petusky
28% 1-year accuracy
20 / 71 met price target
63%upside
$2.25
Outperform
Maintained
12 Mar 2025

Financial journalist opinion

Based on 5 articles about OPK published over the past 30 days

Neutral
Seeking Alpha
7 hours ago
OPKO Health, Inc. (OPK) Q1 2025 Earnings Call Transcript
OPKO Health, Inc. (NASDAQ:OPK ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Yvonne Briggs - Alliance Advisors IR Dr. Phillip Frost - Chairman and CEO Dr. Elias Zerhouni - Vice Chairman and President Adam Logal - Chief Financial Officer Gary Nabel - Chief Innovation Officer Conference Call Participants Maury Raycroft - Jefferies Yi Chen - H. C. Wainwright & Co., LLC Jeffrey Cohen - Ladenburg Thalmann Edward Tenthoff - Piper Sandler Yale Jen - Laidlaw and Company Michael Petusky - Barrington Research Operator Good afternoon, and welcome to the OPKO Health First Quarter 2025 Financial Results Conference Call.
OPKO Health, Inc. (OPK) Q1 2025 Earnings Call Transcript
Positive
Zacks Investment Research
7 hours ago
OPKO Health (OPK) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for OPKO Health (OPK) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
OPKO Health (OPK) Reports Q1 Earnings: What Key Metrics Have to Say
Negative
Zacks Investment Research
8 hours ago
OPKO Health (OPK) Reports Q1 Loss, Lags Revenue Estimates
OPKO Health (OPK) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.12 per share a year ago.
OPKO Health (OPK) Reports Q1 Loss, Lags Revenue Estimates
Positive
Zacks Investment Research
1 week ago
Down -24.31% in 4 Weeks, Here's Why OPKO Health (OPK) Looks Ripe for a Turnaround
OPKO Health (OPK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down -24.31% in 4 Weeks, Here's Why OPKO Health (OPK) Looks Ripe for a Turnaround
Neutral
GlobeNewsWire
3 weeks ago
OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program
MIAMI, April 04, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized an increase of $100 million to the Company's existing common stock repurchase program, bringing the aggregate capacity of the program to $200 million. Approximately $41 million of OPKO's common stock has been repurchased under the existing program since its authorization in July 2024.
OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program
Positive
Zacks Investment Research
1 month ago
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
OPK's growth is fueled by Rayaldee's success and promising pipeline progress. However, margin pressure and overdependence on its lead product are concerning.
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
Positive
Reuters
1 month ago
OPKO and Entera partner to develop obesity pill
OPKO Health and Entera Bio are partnering to develop a once-daily pill for patients with obesity and other disorders, the companies said on Monday.
OPKO and Entera partner to develop obesity pill
Neutral
PRNewsWire
1 month ago
Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses
Transaction to extend Labcorp's leadership in oncology and expand access to the company's high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI , March 11, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health.
Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses
Positive
Zacks Investment Research
2 months ago
OPK Stock Gains Following Q4 Earnings Beat, Gross Margin Expands
The strength in OPKO Health's transfer of intellectual property and other revenues boosts its overall fourth-quarter 2024 performance despite lower RAYALDEE sales.
OPK Stock Gains Following Q4 Earnings Beat, Gross Margin Expands
Neutral
Zacks Investment Research
2 months ago
OPKO Health (OPK) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
OPKO Health (OPK) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Charts implemented using Lightweight Charts™